Table 3.

Analysis of factors potentially associated with all-cause long-term mortality

3A. Univariate Cox regression analysis
Risk Factor (N=322 unless noted)	HR	95% CI	P
Age at BMT (per 10 year increase)	1.1	1.0, 1.2	0.21
Transplant Jan ’07–Dec ’09 vs. Jan’10–Jan’13	1.2	0.9, 1.6	0.24
KPS score (≤ 80 vs. ≥ 90)	1.2	0.8, 1.6	0.40
HCT on Admission (<25 vs. ≥25%)	1.5	1.0, 2.2	0.028
Disease risk (Low, Intermediate, High.)			0.007
Intermediate vs. Low	1.2	0.8, 1.9	0.275
High vs. Low	1.9	1.4, 2.7	0.0002
Female to Male vs. other combinations	0.8	0.6, 1.2	0.403
HLA Match			0.018
10/10 Unrelated donor vs. 10/10 Sibling	1.6	1.0, 2.7	0.06
<10/10 Match vs. 10/10 Sibling	2.2	1.3, 3.9	0.005
Conditioning Regimen			0.585
Reduced Intensity vs. Nonmyeloablative	1.1	0.6, 1.8	0.845
Myeloablative vs. Nonmyeloablative	0.9	0.5, 1.6	0.692
Immunosuppression CSA vs. FK506	1.0	0.7, 1.6	0.820
AGvHD score			<0.0001
aGvHD, grade 2 vs. 0–1	1.2	0.8, 1.7	0.463
aGvHD, grades 3–4 vs. 0–1	2.6	1.8, 3.8	<0.0001
Average age of RBC units (10d incr, N=288)	0.7	0.5, 0.9	0.0096
Pre-HSCT ferritin: (> 1146 vs. ≤1146 ng/ml, N=299)	1.3	0.9, 1.8	0.13
Transfused RBC units (> 5 vs. ≤ 5)	1.8	1.3, 2.4	0.0002
Transfused platelet units (> 2 vs. ≤ 2)	1.6	1.2, 2.2	0.0023

3B. Multivariate Cox regression analysis
Risk Factor (N=322)	HR	95% CI	P	Reliability
HCT on Admission (<25 vs ≥25%)	1.2	0.8, 1.8	0.391	16%
Disease risk (Low, Intermediate, High)			0.018	79%
Intermediate vs. Low	1.3	0.8, 1.9	0.260
High vs. Low	1.7	1.2, 2.4	0.005
HLA Match			0.413	25%
10/10 Unrelated donor vs. 10/10 Sibling	1.3	0.9, 1.8	0.190
<10/10 Match vs. 10/10 Sibling	1.2	0.8, 1.9	0.392
Transfused RBC units (> 5 vs. ≤ 5)	1.4	1.0, 2.0	0.054	71%
Transfused platelet units (> 2 vs. ≤ 2)	1.2	0.9, 1.7	0.250	34%